A recent study analyzed the long-term efficacy and safety profile of anti–tumor necrosis factor (anti-TNF) treatment in 15 patients with rhupus, a rare association defined by the coexistence of both systemic lupus erythematosus and rheumatoid arthritis (RA) in the same patient.
A study published in December 2017 analyzed the long-term efficacy and safety profile of anti—tumor necrosis factor (anti-TNF) treatment in 15 patients with rhupus, a rare association defined by the coexistence of both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in the same patient. Authors of the study note that, to date, there have been no previous studies regarding the use of anti-TNF agents in the treatment of rhupus.
Researchers conducted an open-label, single-center pilot study comprising 15 patients diagnosed with rhupus from 2003 to 2012 with a disease activity score for 28 joints (DAS28) over 3.2. Patients were monitored at 3, 6, 12, 24, and 60 months using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and DAS28.
Of the 15 patients included in the study, 12 were treated with etanercept for a median duration of 62.5 months, and 3 patients were given adalimumab for a median of 36 months. At baseline, median DAS28 and SLEDAI were 5.94 and 6, respectively, in the 2 groups. After 3 months of treatment, DAS28 and SLEDAI decreased to 3.7 and 4, respectively. The authors found that the tolerability and safety profile of the anti-TNF agents were acceptable, with a severe infection rate of 3 per 100 patient years, and with no lupus flares occurring during the follow-up.
The researchers concluded that anti-TNF treatment resulted in an improvement of articular symptoms with a significant decrease of DAS28 score. The SLEDAI score decreased after 3 months of therapy, and these numbers were sustained during the follow-up. Notably, this score also declined without taking into account the arthritis component of the SLEDAI, which the authors suggest could mean that anti-TNF agents could improve the non-articular features of lupus.
This small-scale study suggested that anti-TNF treatment has a “favorable efficacy, a decrease in the median dose of glucocorticoids, and an acceptable tolerance profile in patients with rhupus with refractive arthritis,” said the researchers.
Reference
Danion F, Sparsa L, Arnaud L, et al. Long-term efficacy and safety of anti-tumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. RMD Open. 2017;3:e000555. doi: 10.1136/rmdopen-2017-000555.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.